Prednisone News and Research

RSS

Researchers successfully evaluate new antibody-based drug for patients with severe asthma

A team of researchers at McMaster University and St. Joseph's Healthcare Hamilton have successfully evaluated a new, antibody-based drug for certain patients with severe asthma.

9 Sep 2014

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson today announced sales of $19.5 billion for the second quarter of 2014, an increase of 9.1% as compared to the second quarter of 2013. Operational results increased 9.4% and the negative impact of currency was 0.3%.

15 Jul 2014

Treating ulcerative colitis and Crohn’s disease

Ulcerative colitis and Crohn’s disease are idiopathic (we don’t know the cause) inflammatory diseases (IBD) of the colon and/or small bowel. They are chronic in that we do not have a medical cure and are differentiated from IBS (irritable bowel syndrome) by inflammation that causes ulcerations of the GI tract.

7 Jul 2014

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen-Cilag International NV today announced its submission of a type II variation to the European Medicines Agency to expand the label for VELCADE (bortezomib) to include its use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated Mantle Cell Lymphoma (MCL).

28 Jun 2014

Research: TB infection among people taking corticosteroid pills may be underestimated

Tuberculosis infection among people taking corticosteroid pills may be underestimated, new research suggests.

26 Jun 2014

Alcoholic liver disease: an interview with Dr Vinood Patel, University of Westminster

Alcoholic liver disease (ALD) is one of the leading causes of death worldwide and also in the UK. As its name indicates this disease arises due to consuming excessive amounts of alcohol (80 g/day) over an extended period, normally 10-20 years.

24 Jun 2014

Takeda decides to terminate development of orteronel for prostate cancer

Takeda Pharmaceutical Company Limited announced today that it has voluntarily decided to end the development program for orteronel (TAK-700) for prostate cancer. The decision follows the results of two Phase 3 clinical trials in metastatic, castration resistant prostate cancer (mCRPC).

19 Jun 2014

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb Company today announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30-June 3.

6 May 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%.

15 Apr 2014

Mayo Clinic research shows RA patients more likely to develop chronic kidney disease

Rheumatoid arthritis patients are likelier than the average person to develop chronic kidney disease, and more severe inflammation in the first year of rheumatoid arthritis, corticosteroid use, high blood pressure and obesity are among the risk factors, new Mayo Clinic research shows.

10 Apr 2014

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013.

20 Feb 2014

High levels of stress hormone cortisol may contribute to risk aversion in traders

High levels of the stress hormone cortisol may contribute to the risk aversion and 'irrational pessimism' found among bankers and fund managers during financial crises, according to a new study.

18 Feb 2014

Researchers demonstrate new approach to treating muscular dystrophy

Researchers at Washington University School of Medicine in St. Louis have demonstrated a new approach to treating muscular dystrophy. Mice with a form of this muscle-weakening disease showed improved strength and heart function when treated with nanoparticles loaded with rapamycin, an immunosuppressive drug recently found to improve recycling of cellular waste.

12 Feb 2014

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics, Inc. today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA™) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013.

11 Dec 2013

Celgene: FIRST trial meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene today announced that data from the FIRST (Frontline Investigation of lenalidomide and dexamethasone vs. standard thalidomide) trial was presented on Sunday 8 December, during the Plenary Scientific Session at the 55th American Society Hematology annual meeting in New Orleans. FIRST (MM-020/IFM 07-01) a phase III, multi-centre study in patients newly diagnosed with multiple myeloma and ineligible for stem cell transplant, included 72 patients from the UK.

11 Dec 2013

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease.

2 Dec 2013

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Rituximab (Rituxan) — a drug commonly used rheumatoid arthritis, granulomatosis with polyangiitis (formerly Wegener's), and certain types of cancers — may be a safe and effective treatment for immunoglobulin G4-related disease (commonly called IgG4-RD), according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Astrazeneca, Janssen To Promote Novel Prostate Cancer Treatment In Japan

...

11 Oct 2013

Astrazeneca, Janssen To Promote Novel Prostate Cancer Treatment In Japan

...

11 Oct 2013

Drug to treat metastatic castration-resistant prostate cancer delays progression of pain and quality of life deterioration in men

Abiraterone acetate, a recently FDA-approved drug used to treat men with metastatic castration-resistant prostate cancer, significantly delays progression of pain and quality of life deterioration when taken in conjunction with prednisone.

25 Sep 2013

Prednisone News and Research

Researchers successfully evaluate new antibody-based drug for patients with severe asthma

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Treating ulcerative colitis and Crohn’s disease

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Research: TB infection among people taking corticosteroid pills may be underestimated

Alcoholic liver disease: an interview with Dr Vinood Patel, University of Westminster

Takeda decides to terminate development of orteronel for prostate cancer

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Mayo Clinic research shows RA patients more likely to develop chronic kidney disease

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

High levels of stress hormone cortisol may contribute to risk aversion in traders

Researchers demonstrate new approach to treating muscular dystrophy

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Celgene: FIRST trial meets primary endpoint in patients newly diagnosed with multiple myeloma

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Astrazeneca, Janssen To Promote Novel Prostate Cancer Treatment In Japan

Astrazeneca, Janssen To Promote Novel Prostate Cancer Treatment In Japan

Drug to treat metastatic castration-resistant prostate cancer delays progression of pain and quality of life deterioration in men

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News